SMART MONEY GROUP

[ORCA]

PTIE 2.50.HAS AN FDA EVENT August 7, 2018IT IS UP FROM 2.15.ON WATCH.FOR NEXT TUESDAY.READ BOLD.
REMOXY ER, the Company’s lead product candidate, is an abuse-deterrent, extended-release, oral formulation of oxycodone, a widely prescribed opioid medication. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of August 7, 2018 for completion of its review of the New Drug Application (NDA) for REMOXY ER.